Intellia Therapeutics shares interim clinical results from the Phase 1 portion of the ongoing Phase 1/2 trial of NTLA-2002 in hereditary angioedema...

This update shares news about recent designations awarded by the US FDA and European Medicines Agency for gene-editing candidates for the treatment of...

Intellia Therapeutics recently shared new positive clinical data from the ongoing Phase 1 trial of NTLA-2002 in hereditary angioedema (HAE). NTLA-2002...

Intellia Therapeutics recently announced that the FDA has cleared an Investigational New Drug application for NTLA-2002, a single-dose in vivo CRISPR...

In this week's clinical trial update, we summarise the ongoing in vivo CRISPR clinical trials for three distinct rare genetic diseases: hereditary...

In 2021, we've seen positive clinical data for the first ever in vivo CRISPR medicines, base editors are heading for the clinic, and CRISPR therapies...

Some of the best links we picked up around the internet

Last week, Intellia Therapeutics announced that it had received clearance to begin a clinical trial for NTLA-2002, an in vivo CRISPR therapy candidate...